Lung cavitation in lung metastases of gastric and non-small-cell lung cancer patients treated with apatinib

Fabiana Letizia Cecere¹, Andres Aguilar², Rafael Rosell^{2

3}

Affiliations

¹ IRCCS- Regina Elena national cáncer Institute, Rome, Italy.
² Institute of Oncology Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain.
³ Germans Trias i Pujol Research Institute and Hospital (IGTP), Badalona, Spain.

Editorial

Fabiana Letizia Cecere et al. Transl Lung Cancer Res. 2019 Aug.

. 2019 Aug;8(4):317-318.

doi: 10.21037/tlcr.2019.08.20.

Fabiana Letizia Cecere¹, Andres Aguilar², Rafael Rosell^{2

3}

¹ IRCCS- Regina Elena national cáncer Institute, Rome, Italy.
² Institute of Oncology Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain.
³ Germans Trias i Pujol Research Institute and Hospital (IGTP), Badalona, Spain.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Cavity development: a potential biomarker for antiangiogenesis agents.
Jiang M, Zhang X. Jiang M, et al. Transl Lung Cancer Res. 2020 Feb;9(1):156-157. doi: 10.21037/tlcr.2019.12.11. Transl Lung Cancer Res. 2020. PMID: 32206563 Free PMC article. No abstract available.

1. Marom EM, Martinez CH, Truong MT, et al. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol 2008;3:351-7. 10.1097/JTO.0b013e318168c7e9 - DOI - PubMed
1. Gafoor K, Patel S, Girvin F, et al. Cavitary Lung Diseases: A Clinical-Radiologic Algorithmic Approach. Chest 2018;153:1443-65. 10.1016/j.chest.2018.02.026 - DOI - PubMed
1. Mi YJ, Liang YJ, Huang HB, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res 2010;70:7981-91. 10.1158/0008-5472.CAN-10-0111 - DOI - PMC - PubMed
1. Lin C, Wang S, Xie W, et al. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway. Oncotarget 2016;7:59236-44. - PMC - PubMed
1. Huang M, Gong Y, Zhu J, et al. A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. Invest New Drugs 2019. [Epub ahead of print]. 10.1007/s10637-019-00811-6 - DOI - PubMed